⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17724661 | 1.00 | — | — | |
| SCHEMBL19002827 | 1.00 | — | — | |
| SCHEMBL1171442 | 0.84 | — | — | |
| SCHEMBL8125367 | 0.84 | — | — | |
| SCHEMBL10516123 | 0.84 | — | — | |
| SCHEMBL8585997 | 0.82 | — | — | |
| SCHEMBL11045946 | 0.80 | — | — | |
| SCHEMBL11045942 | 0.80 | — | — | |
| Cyclohexene SCHEMBL8591210 | 0.80 | — | — | |
| SCHEMBL470725 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4125840-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-02-08 | — | — | EP | claimed |
| EP-2114980-B1 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARM INC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | claimed |
| JP-2011525171-A | — | — | 2011-09-15 | — | — | JP | claimed |
| US-7994139-B2 | Antiviral therapeutic agents | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | claimed |
| EP-2265275-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BioCryst Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| WO-2010036407-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | claimed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | claimed |
| EP-2114980-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | Biocryst Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2009111653-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| WO-2006050161-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | claimed |
| CN-1515673-A | Process for preparing enantiomers of (1R, 4S) -or (1S, 4R) -1-amino-4- (hydroxymethyl) -2-cyclopentene derivatives | ��¡���ӹɷ�����˾ | 2004-07-28 | — | — | CN | claimed |
| CN-1515572-A | Carbocyclic nucleoside semi-sulfate and its application for curing viral infection | — | 2004-07-28 | — | — | CN | claimed |
| CN-1150194-C | Carbocyclic nucleoside hemisulfate and its use in treating viral infections | — | 2004-05-19 | — | — | CN | claimed |
| CN-1317971-A | Antiviral combination comprising lamivudine and abacavir | GLAXO GROUP LTD (GB) | 2001-10-17 | — | — | CN | claimed |
| EP-1141374-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-AMINO-4-(HYDROXYMETHYL)-CYCLOPENT-2-ENE DERIVATIVES | Lonza AG (CH) | 2001-10-10 | — | — | EP | claimed |
| CN-1306430-A | Combinations comprising VX478, zidovuding and/or 1592U89 for use in treatment of HIV | GLAXO GROUP LTD (GB) | 2001-08-01 | — | — | CN | claimed |
| CN-1263529-A | Carbocyclic nucleoside hemisulfate and its use in treating viral infections | GLAXO GROUP LTD (GB) | 2000-08-16 | — | — | CN | claimed |
| WO-2000039324-A2 | METHOD FOR PRODUCING OPTICALLY ACTIVE 1-AMINO-4-(HYDROXYMETHYL)-CYCLOPENT-2-ENE DERIVATIVES | LONZA AG (CH) | 2000-07-06 | — | — | WO | claimed |
| CN-1201794-A | Process for the preparation of (1S,4R) -or (1R,4S) -4- (2-amino-6-chloro-9H-purin-9-yl) -2-cyclopentene-1-methanol or salts thereof | LONZA AG (CH) | 1998-12-16 | — | — | CN | claimed |